

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/33832> holds various files of this Leiden University dissertation

Author: Krens, Lisanne

Title: Refining EGFR-monoclonal antibody treatment in colorectal cancer

Issue Date: 2015-07-02



Chapter 9

L.L. Krens, J.M. Baas, M.C. Verboom, G. Paintaud,
C. Desvignes, H.J. Guchelaar and H. Gelderblom

Cancer Chemother Pharmacol. 2014 Jun;73(6):1303-6



*Pharmacokinetics and safety
of cetuximab in a patient with
renal dysfunction*



Abstract

In the literature data on the effect of renal impairment on the pharmacokinetics of anticancer drugs are scarce. Here, we report a 68 year old metastatic osteosarcoma patient with impaired renal function due to prior chemotherapy, who was treated on compassionate use basis with 400 mg/m² cetuximab. Pharmacokinetic parameters after the first dose, including dose normalised AUC from time zero to day 7 (AUC_{0-7}), clearance (Cl), elimination half-life ($t_{1/2}$) were estimated using trapezoidal non compartmental methods and compared to pharmacokinetic data from a study population with normal kidney function. These results showed that the pharmacokinetics of cetuximab in this patient with renal failure was similar to that with adequate renal function and suggests that cetuximab can be safely used in cancer patients with renal impairment without dose adjustment.

Introduction

Cetuximab is a monoclonal antibody, targeting epidermal growth factor receptor (EGFR) and registered for the treatment of colorectal and head and neck cancer. During its development, the drug has been investigated in patients with adequate renal and hepatic function only and a dose of 250 mg/m² every week, after an initial loading dose of 400 mg/m², is defined in the summary of product characteristics.

No specific dose recommendations are given for patients with renal impairment (http://packageinserts.bms.com/pi/pi_erbitux.pdf). The elimination of antibodies occurs via both nonspecific intracellular catabolism, following fluid-phase endocytosis, and receptor-mediated elimination after binding to their target antigen. Part of cetuximab clearance is therefore explained by binding to EGFR. Clearance of the EGFR antibody cetuximab seems independent of the liver and kidney function[1]. In addition, there are four case reports[2-5] of haemodialysis patients who could safely be treated with standard doses of cetuximab. The aim of this study was to determine the pharmacokinetics of the conventional dose cetuximab in patients with impaired renal function and to compare it to published data obtained in populations of cetuximab treated patients with normal renal function.

Method

Case presentation

We treated a 68 year old metastatic osteosarcoma patient with impaired renal function due to prior chemotherapy on compassionate use basis with 400 mg/m² cetuximab. The serum creatinine of this patient was 128 µmol/L. The glomerular filtration rate (GFR) was 35 mL/min/173 m², calculated with the MDRD formula ($0.742 * 175 * \text{Serum creatinine}^{-1.154} * \text{Age}^{0.203}$). The GFR, calculated with the Cockcroft-Gault formula was 41 mL/min ($0.85 * (140 - \text{Age}) * \text{Weight} / (72 * \text{Serum creatinine})$). This treatment was based on preclinical data on cetuximab activity in osteosarcoma[6] and the lack of other treatment options. The medical ethical committee approved the treatment and the pharmacokinetic analysis and the patient gave informed consent. The starting dose was 740 mg, preceded by the recommended 2 mg of the antihistamine clemastine, to avoid an allergic reaction to cetuximab.

Sample collection

Cetuximab was infused over two hours. Serum samples were collected 2, 3.5, 4.5, 44 and 168 hours after the end of the infusion in line with a previous pharmacokinetic study[7]. Cetuximab serum concentrations were measured using a validated immunoassay[8]. Limit of detection was 0.012 µg/mL and lower limit of quantitation (LLOQ) was 0.75 µg/mL.

Pharmacokinetic parameters

Pharmacokinetic parameters after the first dose, including dose normalised AUC from time zero to day 7 (AUC_{0-7}), clearance (Cl), elimination half-life ($t_{1/2}$) were estimated by trapezoidal non compartmental methods using MW/PHARM 3.5 (Mediware, Groningen, The Netherlands). Results were compared to historical data on cetuximab in patients with normal renal function as reported by Tan et al.[9] Fracasso et al.[10] and Thariat et al.[2].

Results

The maximum concentration (C_{max}), measured at the end of the 2 hour infusion, in this patient was 297 $\mu\text{g}/\text{mL}$, the minimum concentration (C_{min} or trough level) was 34.4 $\mu\text{g}/\text{mL}$. The reported serum concentration profile, shown in figure 1, was used to calculate the AUC, Cl and $t_{1/2}$. In table 1, an overview of the pharmacokinetics of cetuximab in study populations with normal renal function and in this case are shown (2;9;10). In this table the pharmacokinetics after a single dose of 400 mg/m^2 are depicted, and are used for comparison.




Figure 1: Time curve of cetuximab serum concentration following two hour infusion of 740 mg cetuximab in a patient with a glomerular filtration rate of approximately 35 mL per minute.

In this patient the calculated AUC after the first dose was 20,280 $\mu\text{g}\cdot\text{day}/\text{mL}$. The half-life after a single dose of cetuximab was 53.2 hours with a calculated clearance of 32.6 mL/h. The C_{max} was approximately 30% higher compared to the C_{max} in the studies of Tan et al. and Fracasso et al. (9;10) The other parameters Cl, AUC, $T_{1/2}$ and V are comparable as reported in those 2 studies. The half-life of cetuximab in our patient is 30% shorter than that calculated in the studies.

During the first course of cetuximab, the patient experienced adverse effects: reversible grade 2 hallucinations and fatigue. After careful considerations these symptoms were deemed to be most likely caused by the 2 mg clemastine. Due to these side effects the patient refused further treatment with cetuximab. Little is known about the pharmacokinetics of clemastine, nonetheless, normally no dose reductions are advised in patient with renal impairment.

Cetuximab-related side effects such as skin toxicity and diarrhoea did not occur in this patient during the first course.

Table 1: Pharmacokinetic parameters of the case and historical data from three studies.

Study	GFR/ serum creatinin range	model	Dose	C _{max} µg/mL	C _{min} µg/mL	AUC ₀₋₇ h*mg/L	CL mL/h	T _½ Hours	V Litre
Case	±35 mL/min	Non compartmental model	740 mg (400 mg/m ²)	297.0	34.4	20,280	32.6	53.2	2.48
Tan et al. 2006	Creatinine ≤ 1.5 times upper limit of normal	Non compartmental model	400 mg/m ² single dose	205.0 (65.7)	n/a	19,000 (7,802)	21.5 (7.68)	75.10 (15.9)	2.44 (0.43)
Fracasso et al. 2007	Creatinine ≤ 1.5 times upper limit of normal	Non compartmental model	400 mg/m ² single dose	228.9 (6,5)	n/a	24,620 (9,555)	43.6 (15.8)	97.5 (20.7)	4.8 (2.2)
Thariat et al. 2008	hemodialysis	Two-compartment model with first order elimination	250 mg/m ²	n/a	n/a	n/a	25	285	7.56

Abbreviation: n/a = not applicable

Discussion

This case report shows that the pharmacokinetics of cetuximab in a patient with renal failure is similar to that with adequate renal function. Different studies investigated the pharmacokinetics of cetuximab in population with adequate renal function. For the comparison, studies with single doses were used. Most of the studies reported cetuximab pharmacokinetic parameters at steady state after a loading dose of 400 mg/m² followed by weekly doses of 250 mg/m². Using a loading dose, steady state is usually reached within three weeks. Since this patient discontinued therapy after one single infusion, we can only compare this single dose to similar administrations available in the literature.

Our study shows some difference between the estimated parameters in our patient and patients with normal renal function. Due to inter patient variability, nonetheless, overall the kinetic profile is in line with the population with adequate renal function. Cetuximab pharmacokinetics are not studied in patients with impaired renal function, four case reports[2-5] studied the kinetics of cetuximab in patients undergoing haemodialysis. These four case studies showed that cetuximab in a patient with haemodialysis may be safely used. The estimated pharmacokinetic parameters were comparable to cetuximab patients with normal kidney function. Our study shows, for the first time, that pharmacokinetic parameters were also not altered in a patient with decreased renal function without haemodialysis.

At 3.5 hours, a lower cetuximab concentration was measured compared to the concentration measured at 4.5 hours. This appears to be noise from a single patient because these time points were very close to each other, these concentrations were measured shortly after infusion of cetuximab and the concentration of cetuximab decreases only slowly at this interval. Many drugs that enter the market are studied in a patient population with normal renal function and no dose recommendations are made for patients with impaired organ function and formal organ impairment studies are lacking. This is also the case for cetuximab. Other than from common

sense and four case reports in haemodialysis patients there was no information available to guide our decision on how to use cetuximab in this patient. As renal impairment is a common problem in head and neck cancer patients due to prior cisplatin chemotherapy and in colorectal cancer patients due to the high incidence of the disease our finding of no clinically relevant alteration of cetuximab pharmacokinetics in our patient with impaired renal function has clinical importance for dose guidance in future patients.

Acknowledgements

Measurement of cetuximab serum concentrations were carried out within the CePiBAC platform of Tours University Hospital. CePiBAC is co-financed by the European Union.

References

- 1 Blick SK, Scott LJ. (2007) Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer. *Drugs*; 67(17):2585-607.
- 2 Thariat J, Azzopardi N, Peyrade F, Launay-Vacher V, Santini J, Lecomte T et al. (2008) Cetuximab pharmacokinetics in end-stage kidney disease under hemodialysis. *J Clin Oncol*; 26(25):4223-5.
- 3 Inauen R, Cathomas R, Boehm T, Koeberle D, Pestalozzi BC, Gillessen S et al. (2007) Feasibility of using cetuximab and bevacizumab in a patient with colorectal cancer and terminal renal failure. *Oncology*; 72(3-4):209-10.
- 4 Aldoss IT, Plumb T, Zhen WK, Lydiatt DD, Ganti AK. (2009) Cetuximab in hemodialysis: a case report. *Head Neck*; 31(12):1647-50.
- 5 Fontana E, Pucci F, Ardizzoni A. (2013) Colorectal cancer patient on maintenance dialysis successfully treated with cetuximab. *Anticancer Drugs*.
- 6 Pahl JH, Ruslan SE, Buddingh EP, Santos SJ, Szuhai K, Serra M et al. (2012) Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma. *Clin Cancer Res* 18(2):432-41.
- 7 Azzopardi N, Lecomte T, Ternant D, Boisdron-Celle M, Piller F, Morel A et al. (2011) Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. *Clin Cancer Res* 17(19):6329-37.
- 8 Ceze N, Ternant D, Piller F, Degenne D, Azzopardi N, Dorval E et al. (2009) An enzyme-linked immunosorbent assay for therapeutic drug monitoring of cetuximab. *Ther Drug Monit*; 31(5):597-601.
- 9 Tan AR, Moore DF, Hidalgo M, Doroshow JH, Poplin EA, Goodin S et al. (2006) Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors. *Clin Cancer Res*; 12(21):6517-22.
- 10 Fracasso PM, Burris H, III, Arquette MA, Govindan R, Gao F, Wright LP et al. (2007) A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing. *Clin Cancer Res*; 13(3):986-93.